Unknown

Dataset Information

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.


ABSTRACT: Multigene assays can provide insight into key biological processes and prognostic information to guide development and selection of adjuvant cancer therapy. We report a comprehensive genomic and transcriptomic analysis of tumor samples from 171 patients at high risk for recurrent renal cell carcinoma post nephrectomy from the S-TRAC trial (NCT00375674). We identify gene expression signatures, including STRAC11 (derived from the sunitinib-treated population). The overlap in key elements captured in these gene expression signatures, which include genes representative of the tumor stroma microenvironment, regulatory T cell, and myeloid cells, suggests they are likely to be both prognostic and predictive of the anti-angiogenic effect in the adjuvant setting. These signatures also point to the

SUBMITTER: Motzer RJ 

PROVIDER: S-EPMC9550765 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature